Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is -4.85% lower on its value in year-to-date trading and has touched a low of $95.49 and a high of $148.06 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The JAZZ stock was last observed hovering at around $116.96 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $117.18, the stock is 8.83% and -6.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.31 million and changing 0.19% at the moment leaves the stock -1.34% off its SMA200. JAZZ registered 5.36% gain for a year compared to 6-month gain of 5.22%. The firm has a 50-day simple moving average (SMA 50) of $124.8942 and a 200-day simple moving average (SMA200) of $118.76865.
The stock witnessed a -6.25% loss in the last 1 month and extending the period to 3 months gives it a -6.29%, and is 7.52% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.69% over the week and 5.36% over the month.
Jazz Pharmaceuticals plc (JAZZ) has around 2800 employees, a market worth around $7.22B and $4.07B in sales. Current P/E ratio is 13.47 and Fwd P/E is 5.17. Profit margin for the company is 13.77%. Distance from 52-week low is 22.71% and -20.85% from its 52-week high. The company has generated returns on investments over the last 12 months (5.48%).
with sales reaching $983.75M over the same period.The EPS is expected to grow by 11.39% this year, but quarterly earnings will post 5.41% year-over-year. Quarterly sales are estimated to grow 9.07% in year-over-year returns.
718.0 institutions hold shares in Jazz Pharmaceuticals plc (JAZZ), with institutional investors hold 102.58% of the company’s shares. The shares outstanding are 60.63M, and float is at 58.83M with Short Float at 7.71%. Institutions hold 99.65% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.32 million shares valued at $674.82 million. The investor’s holdings represent 10.0549 of the JAZZ Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 6.15 million shares valued at $655.94 million to account for 9.7735 of the shares outstanding. The other top investors are LSV ASSET MANAGEMENT which holds 2.48 million shares representing 3.9448 and valued at over $264.75 million, while CAPITAL WORLD INVESTORS holds 3.2117 of the shares totaling 2.02 million with a market value of $215.55 million.
Jazz Pharmaceuticals plc (JAZZ) Insider Activity
Jazz Pharmaceuticals plc disclosed in a document filed with the SEC on Apr 01 ’25 that COZADD BRUCE C (Chairman & CEO) sold a total of 1,500 shares of the company’s common stock. The trade occurred on Apr 01 ’25 and was made at $123.75 per share for $0.19 million. Following the transaction, the insider now directly holds 0.44 million shares of the JAZZ stock.
Still, SEC filings show that on Apr 01 ’25, COZADD BRUCE C (Officer) Proposed Sale 2,000 shares at an average price of $125.31 for $0.25 million. The insider now directly holds shares of Jazz Pharmaceuticals plc (JAZZ).
